vs
RBC Bearings INC（RBC）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是RBC Bearings INC的1.3倍（$622.0M vs $461.6M），Royalty Pharma plc净利率更高（34.4% vs 14.6%，领先19.8%），RBC Bearings INC同比增速更快（17.0% vs 4.8%），过去两年RBC Bearings INC的营收复合增速更高（5.6% vs 4.6%）
该文本实际介绍的并非RBC Bearings，而是美国多佛公司。多佛是一家工业产品综合制造商，1955年成立，总部位于伊利诺伊州当纳斯格罗夫。2021年其业务分为五大板块：工程产品、清洁能源与加注、成像与识别、泵与工艺解决方案、气候与可持续技术，是标普500成分股，在纽约证券交易所上市。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
RBC vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.3倍
$461.6M
营收增速更快
RBC
高出12.3%
4.8%
净利率更高
RPRX
高出19.8%
14.6%
两年增速更快
RBC
近两年复合增速
4.6%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $461.6M | $622.0M |
| 净利润 | $67.4M | $214.2M |
| 毛利率 | 44.3% | — |
| 营业利润率 | 22.3% | 62.4% |
| 净利率 | 14.6% | 34.4% |
| 营收同比 | 17.0% | 4.8% |
| 净利润同比 | 16.4% | 2.9% |
| 每股收益（稀释后） | $2.13 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RBCRPRX
| Q4 25 | $461.6M | $622.0M | ||
| Q3 25 | $455.3M | $609.3M | ||
| Q2 25 | $436.0M | $578.7M | ||
| Q1 25 | $437.7M | $568.2M | ||
| Q4 24 | $394.4M | $593.6M | ||
| Q3 24 | $397.9M | $564.7M | ||
| Q2 24 | $406.3M | $537.3M | ||
| Q1 24 | $413.7M | $568.0M |
净利润RBCRPRX
| Q4 25 | $67.4M | $214.2M | ||
| Q3 25 | $60.0M | $288.2M | ||
| Q2 25 | $68.5M | $30.2M | ||
| Q1 25 | $72.7M | $238.3M | ||
| Q4 24 | $57.9M | $208.2M | ||
| Q3 24 | $54.2M | $544.0M | ||
| Q2 24 | $61.4M | $102.0M | ||
| Q1 24 | — | $4.8M |
毛利率RBCRPRX
| Q4 25 | 44.3% | — | ||
| Q3 25 | 44.1% | — | ||
| Q2 25 | 44.8% | — | ||
| Q1 25 | 44.2% | — | ||
| Q4 24 | 44.3% | — | ||
| Q3 24 | 43.7% | — | ||
| Q2 24 | 45.3% | — | ||
| Q1 24 | 43.1% | — |
营业利润率RBCRPRX
| Q4 25 | 22.3% | 62.4% | ||
| Q3 25 | 21.5% | 70.1% | ||
| Q2 25 | 23.2% | 36.3% | ||
| Q1 25 | 23.0% | 94.0% | ||
| Q4 24 | 21.7% | 60.9% | ||
| Q3 24 | 21.6% | — | ||
| Q2 24 | 24.0% | 50.2% | ||
| Q1 24 | 22.8% | -13.0% |
净利率RBCRPRX
| Q4 25 | 14.6% | 34.4% | ||
| Q3 25 | 13.2% | 47.3% | ||
| Q2 25 | 15.7% | 5.2% | ||
| Q1 25 | 16.6% | 41.9% | ||
| Q4 24 | 14.7% | 35.1% | ||
| Q3 24 | 13.6% | 96.3% | ||
| Q2 24 | 15.1% | 19.0% | ||
| Q1 24 | — | 0.8% |
每股收益（稀释后）RBCRPRX
| Q4 25 | $2.13 | $0.49 | ||
| Q3 25 | $1.90 | $0.67 | ||
| Q2 25 | $2.17 | $0.07 | ||
| Q1 25 | $2.33 | $0.55 | ||
| Q4 24 | $1.82 | $0.46 | ||
| Q3 24 | $1.65 | $1.21 | ||
| Q2 24 | $1.90 | $0.23 | ||
| Q1 24 | $1.92 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $107.6M | $618.7M |
| 总债务越低越好 | $990.2M | $9.0B |
| 股东权益账面价值 | $3.3B | $9.7B |
| 总资产 | $5.1B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.30× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资RBCRPRX
| Q4 25 | $107.6M | $618.7M | ||
| Q3 25 | $91.2M | $938.9M | ||
| Q2 25 | $132.9M | $631.9M | ||
| Q1 25 | $36.8M | $1.1B | ||
| Q4 24 | — | $929.0M | ||
| Q3 24 | — | $950.1M | ||
| Q2 24 | $76.8M | $1.8B | ||
| Q1 24 | $63.5M | $843.0M |
总债务RBCRPRX
| Q4 25 | $990.2M | $9.0B | ||
| Q3 25 | $1.1B | $8.9B | ||
| Q2 25 | $915.6M | $8.0B | ||
| Q1 25 | $920.1M | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | $1.2B | $6.1B |
股东权益RBCRPRX
| Q4 25 | $3.3B | $9.7B | ||
| Q3 25 | $3.2B | $9.6B | ||
| Q2 25 | $3.1B | $9.5B | ||
| Q1 25 | $3.0B | $9.8B | ||
| Q4 24 | $2.9B | $10.3B | ||
| Q3 24 | $2.9B | $10.3B | ||
| Q2 24 | $2.8B | $9.8B | ||
| Q1 24 | $2.8B | $9.9B |
总资产RBCRPRX
| Q4 25 | $5.1B | $19.6B | ||
| Q3 25 | $5.1B | $19.3B | ||
| Q2 25 | $4.8B | $18.3B | ||
| Q1 25 | $4.7B | $17.6B | ||
| Q4 24 | $4.7B | $18.2B | ||
| Q3 24 | $4.7B | $18.0B | ||
| Q2 24 | $4.7B | $17.7B | ||
| Q1 24 | $4.7B | $16.1B |
负债/权益比RBCRPRX
| Q4 25 | 0.30× | 0.92× | ||
| Q3 25 | 0.34× | 0.93× | ||
| Q2 25 | 0.29× | 0.84× | ||
| Q1 25 | 0.30× | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | 0.43× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $122.1M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $99.1M | — |
| 自由现金流率自由现金流/营收 | 21.5% | — |
| 资本支出强度资本支出/营收 | 5.0% | — |
| 现金转化率经营现金流/净利润 | 1.81× | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流RBCRPRX
| Q4 25 | $122.1M | $827.1M | ||
| Q3 25 | $88.4M | $702.6M | ||
| Q2 25 | $120.0M | $364.0M | ||
| Q1 25 | — | $596.1M | ||
| Q4 24 | $84.0M | $742.5M | ||
| Q3 24 | — | $703.6M | ||
| Q2 24 | $97.4M | $658.2M | ||
| Q1 24 | — | $664.6M |
自由现金流RBCRPRX
| Q4 25 | $99.1M | — | ||
| Q3 25 | $71.7M | — | ||
| Q2 25 | $104.3M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $73.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $88.4M | — | ||
| Q1 24 | — | — |
自由现金流率RBCRPRX
| Q4 25 | 21.5% | — | ||
| Q3 25 | 15.7% | — | ||
| Q2 25 | 23.9% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 18.7% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 21.8% | — | ||
| Q1 24 | — | — |
资本支出强度RBCRPRX
| Q4 25 | 5.0% | — | ||
| Q3 25 | 3.7% | — | ||
| Q2 25 | 3.6% | — | ||
| Q1 25 | 3.2% | — | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 4.1% | — | ||
| Q2 24 | 2.2% | — | ||
| Q1 24 | — | — |
现金转化率RBCRPRX
| Q4 25 | 1.81× | 3.86× | ||
| Q3 25 | 1.47× | 2.44× | ||
| Q2 25 | 1.75× | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | 1.45× | 3.57× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | 1.59× | 6.45× | ||
| Q1 24 | — | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RBC
| Domestic | $413.3M | 90% |
| Foreign | $48.3M | 10% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
